Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

Multidisciplinary Approach in Muscle-Invasive Bladder Cancer

March 27th 2015

Neoadjuvant and Adjuvant Therapy in Bladder Cancer

March 27th 2015

Managing Renal Pelvis Transitional Cell Carcinoma

March 27th 2015

Lymph Node Dissection in Bladder Cancer

March 27th 2015

Introduction: Neoadjuvant Chemotherapy in Bladder Cancer

March 27th 2015

Advanced Bladder Cancer Increases Suicide Risk, Study Says

March 27th 2015

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.

Genetic Testing in RCC

March 26th 2015

Immune Checkpoint Inhibition in RCC

March 26th 2015

Second-Line Cabozantinib in mRCC

March 26th 2015

Second-Line Treatments in RCC

March 26th 2015

Investigational Approaches in RCC

March 26th 2015

VEGF Versus mTOR in Non-Clear Cell RCC

March 26th 2015

Sunitinib Versus Pazopanib in Renal Cell Carcinoma

March 26th 2015

Managing Untreated Metastatic Renal Cell Carcinoma

March 26th 2015

Role of Radiation Therapy in Renal Cell Carcinoma

March 26th 2015

Introduction: Surgical Approaches in mRCC

March 26th 2015

Refining Approaches to Reach Treatment Goals in mRCC

March 26th 2015

Patricia Hofstra on Alternatives to Acquisition in Healthcare

March 25th 2015

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.